Please login to the form below
New accounts: February
The following table lists new pharmaceutical account wins notified to us by the winning agencies for the period November 2005 to January 2006 inclusive
The following table lists new pharmaceutical account wins notified to us by the winning agencies for the period November 2005 to January 2006 inclusive. Please note that inclusion in this table does not necessarily indicate exclusivity and other agencies may also be involved with some of the products listed in other ways, or in domestic, overseas or international markets.
To submit an entry for New Accounts, email nhobson@pmlive.com
|
|
|
|
|
|
Astellas |
Pan-European corporate profiling |
Corporate |
The Choice Group |
|
Boehringer Ingelheim/Lilly UK |
Cymbalta |
Neurology |
Virgo Health PR |
|
Cephalon |
Actiq |
Pain |
TVF Communications |
|
Novartis |
Aclasta |
CRM |
MRM Worldwide |
|
Novartis |
Prexige |
Osteoarthritic pain |
Clew Communications |
|
Novartis |
Transplantation portfolio |
Transplantation |
LeapFrog Medical |
|
Pfizer |
Diovan/Codiovan |
Hypertension |
TVF Communications |
|
Pfizer |
Injectable contraceptive |
Contraception |
Ruder Finn |
|
Roche |
Avastin |
Oncology |
Ketchum |
|
Solvay |
Omacor |
Cardiology |
LeapFrog Medical |
|
UCB Pharma |
Equasym XL |
ADHD |
TVF Communications |
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
-
SENIOR MEDICAL WRITER
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- Senior Account Director - Med Comms Agency
-
Salary TBC
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- AZ/Oxford University vaccine shows 82.4% efficacy with extended dosing schedule
- Pfizer/BioNTech to develop a booster dose for their COVID-19 vaccine
- STEM Healthcare founder Rob Wood secures a 25% stake in performance-io
- GSK launches late-stage testing of RSV vaccine candidate in older adults
- FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz
- FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine
- UK introduces Rare Diseases Framework to improve the lives of people with rare diseases
- Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease
- UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’
- Merck to acquire Pandion Therapeutics for $1.85bn
- bluebird bio marks Rare Disease Day 2021 with launch of patient testimonial video
PMHub
Research Partnership
We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...
Latest intelligence
- 4 ways to recruit Alzheimer’s disease patients for your clinical trial
- What key things do you need to remember to reach patients living with Alzheimer’s disease?...
- Integrating competitive intelligence into business development, licensing and M&A strategy
- The advantages of partnering with a competitive intelligence or knowledge management team...
- Reaching patients and HCPs during the pandemic
- COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
Quick links
Infographics
